WORLDWIDE MARKET FOR PROTEIN DRUGS

Protein drugs represent one of the areas of fastest growth within
pharmaceuticals. From literally zero sales a decade ago, there are now
multiple blockbuster protein drugs. Driving the growth are a number of new
drugs, which are markedly superior to existing small-molecule drugs. While
protein-based therapeutics can be remarkably more expensive than
traditional small-molecule drugs (for example, the widely used TNF-alpha
inhibitors cost over $10,000 per patient per year), patients, doctors and
insurers all agree that the new therapies are superior to their cheaper
predecessors. In addition, many biologics can treat diseases, which are
untouched by small-molecule drugs.

According to a soon-to-be-released updated report from Business
Communications Company, Inc. (www.bccresearch.com)  RC-065U The
Market for Bioengineered Protein Drugs, in 2002, drug companies sold nearly
$33 billion in protein drugs, and we project they will sell close to $40 billion in
2003.

We predict that sales of these drugs will continue to grow faster than
pharmaceutical's overall historic growth rate of 8% annually. The market for
protein drugs will grow at an AAGR (average annual growth rate) of 12.2%
from 2003 through 2008 to reach nearly $71 billion. Several important new
drugs should receive FDA approval for sale, and previously introduced
biologics will continue to strip market share from older, less effective
therapies. Most notably, there are a number of monoclonal antibodies in the
last stages of clinical trials for the treatment of autoimmune disease and
cancer that promise to be blockbusters.

While growth of protein drugs should be healthy, industry participants in the
market also face serious and new challenges. Notably, lawmakers are
threatening to introduce bills governing the introduction of generic drugs, and
several leading drugs will lose their patent protection within the timeframe of
this study. This would be historically important, since there are neither
generic protein drugs currently on the market, nor is there any framework for
the introduction of generic protein drugs.

At the same time, the drug-discovery process has been turned upside down
through the use of technologies such as high-throughput screening,
genomics, proteomics, rational drug design and other technologies. In
particular, the immune system is one of the most complex systems known to
man; these new technologies are revealing hundreds of possible targets for
the treatment of immune disease.

While all medicines in existence are aimed at one of 500 targets, one can
conservatively estimate that there are between 3,000 and 10,000 possible
targets based on the estimated number of proteins. Many of these new
targets represent excellent opportunities for the development of protein drugs.

These new technologies are just starting to affect the drug industry. As a
result, over the next 5 years the amount of money the pharmaceutical industry
devotes to product development will rise sharply; the number of drugs
brought to market will start to rise, but not proportionately.


       Worldwide Sales of Protein Drugs, through 2008
                                   ($ Millions)
                                                                   2002   2003    2008           AAGR %
                                                                                                          2003-2008
Replacement proteins                                                  26,711   31,423  50,091       9.8
Monoclonal antibodies and fusion proteins                   6,226      8,478  20,860      19.7
Total                                                                            32,937    39,901  70,951     12.2

Source: BCC, Inc.


HOME
PHARMCEUTICAL
INDUSTRY

Foundamental
Science
Colloidal Stabilization

Drug Product
Development
Patent Application
Product Development
Product Ingredients
Colorant
Scale up a batch 1
Drug Delivery Industry
Drug Delivery - Smart
Bomb
Lotion, Cream, Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR Coating-Aquacoat

Drug Industry
Drug Competitions
Drug in Development
Cholesterol-lowering
Drug-Terminologies
Packaging Materials

Market
Drug Dev- 2004
Drug Dev - 2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market

Novo Norkdisk R&D

Equipment
Blenders

CONTRACT
MANUFACT.
Nutrition Supplements

NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Duodote
Erbitux (cetuximab)
Gardasil
GNDF
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm (Lidocaine)
Liraglutide
Lucentis
Lyrica (pregabalin)
Prezista
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Tykerb
Tysabri
Vectibix
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2

Double-blind Study